Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Stock Information for Zevra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zevra Therapeutics Inc.

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Zevra Therapeutics to Participate in the Citizens Life Science Conference
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.